Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical DocumentClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHF Research FoundationHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaStatementSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Feb 13 2022 | HFSA President's Update: February 2022 HFSA News President's Updates Read More Feb 7 2022 | Cytokinetics announces FDA acceptance of new drug application for omecamtiv mecarbil for the treatment of heart failure with reduced ejection fraction Industry News Industry Read More Jan 24 2022 | HFSA Releases Review Examining the Growing Economic Burden of Heart Failure in the United States HFSA News Journal of Cardiac Failure Research Read More Jan 24 2022 | Eplontersen granted Orphan Drug Designation in the US for transthyretin amyloidosis Industry News Industry Read More Jan 23 2022 | HFSA President's Update: January 2022 HFSA News President's Updates Read More Pagination First page « First Previous page ‹ Previous … Page 71 Page 72 Page 73 Page 74 Current page 75 Page 76 Page 77 Page 78 Page 79 … Next page Next › Last page Last »
Feb 7 2022 | Cytokinetics announces FDA acceptance of new drug application for omecamtiv mecarbil for the treatment of heart failure with reduced ejection fraction Industry News Industry Read More
Jan 24 2022 | HFSA Releases Review Examining the Growing Economic Burden of Heart Failure in the United States HFSA News Journal of Cardiac Failure Research Read More
Jan 24 2022 | Eplontersen granted Orphan Drug Designation in the US for transthyretin amyloidosis Industry News Industry Read More
